A phase I clinical trial of replication-competent Ad-HIV vaccines is soon to be initiated in the NIH clinical center in collaboration with NIAID and Dr. Mark Connors as Principal Investigator. The study will evaluate the safety and immunogenicity of Ad4-HIVenv and Ad4-HIVmosaic gag vaccines formulated as enteric coated capsules for oral administration and as a liquid for tonsillar application. A current clinical trial is on-going in which an Ad4-flu vaccine is being tested by the tonsillar route. This study will determine an appropriate dose for the Ad4 vector and will enable jump-starting of the Ad4-HIV vaccine studies. New Ad-recombinants are under development both for future clinical use and for pre-clinical studies in the rhesus macaque model. These include recombinants containing novel envelope inserts intended to generate broad, potent neutralizing antibodies. This work includes assessment of immunogenicity of the newly constructed recombinant vaccines in appropriate animal models. In addition, Ad vectors with deletion of genes not essential for replication of the virus have been developed, and will be used in future preclinical vaccine design. Previously, the STEP trial, a phase III clinical trial of a non-replicating Ad5-HIV vaccine showed lack of protective efficacy in people together with a suggestion that infection might have been enhanced in individuals with pre-existing immunity to Ad5. This trial was modeled in SIV rhesus macaques, and the results were recapitulated in showing no efficacy. However, enhancement of SIV infection following a penile challenge was not confirmed. On-going studies will further evaluate this issue. Overall, our project is focused on moving the replication-competent Ad-recombinant vaccine approach into phase I clinical trials. This is a novel approach, which has shown superior immunogenicity in non-human primate studies in comparison to non-replicating Ad-recombinant vaccines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011063-06
Application #
8763330
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$379,936
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Qureshi, Huma; Genescà, Meritxell; Fritts, Linda et al. (2014) Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques. PLoS One 9:e106004
Thomas, Michael A; Song, Rui; Demberg, Thorsten et al. (2013) Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PLoS One 8:e76344
Qureshi, Huma; Ma, Zhong-Min; Huang, Ying et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86:2239-50
Patterson, L Jean; Kuate, Seraphin; Daltabuit-Test, Mara et al. (2012) Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 19:629-37
Hidajat, Rachmat; Kuate, Seraphin; Venzon, David et al. (2010) Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine 28:3963-71
Demberg, Thorsten; Robert-Guroff, Marjorie (2009) Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 28:20-48
Morgan, Cecilia; Marthas, Marta; Miller, Christopher et al. (2008) The use of nonhuman primate models in HIV vaccine development. PLoS Med 5:e173
Patterson, L Jean; Robert-Guroff, Marjorie (2008) Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 8:1347-63